Analysts at Jefferies Group raised their price objective on shares of Celldex Therapeutics (NASDAQ:CLDX) from $19.00 to $25.00 in a research report issued to clients and investors on Wednesday, ARN reports. Jefferies Group’s price target suggests a potential upside of 25.44% from the company’s current price.
A number of other analysts have also recently weighed in on CLDX. Analysts at Roth Capital raised their price target on shares of Celldex Therapeutics from $16.00 to $34.00 in a research note to investors on Wednesday, July 24th. They now have a “buy” rating on the stock. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Celldex Therapeutics from $16.00 to $24.00 in a research note to investors on Monday, July 8th. They now have a “buy” rating on the stock. Finally, analysts at Guggenheim initiated coverage on shares of Celldex Therapeutics in a research note to investors on Wednesday, July 3rd. They set a “buy” rating and a $24.00 price target on the stock.
Four analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $25.57.
Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 19.93 on Wednesday. Celldex Therapeutics has a one year low of $4.46 and a one year high of $22.40. The stock’s 50-day moving average is currently $18.84. The company’s market cap is $1.612 billion.
Celldex Therapeutics (NASDAQ:CLDX) last released its earnings data on Tuesday, August 6th. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.22) by $0.02. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. The company’s quarterly revenue was down 51.7% on a year-over-year basis. Analysts expect that Celldex Therapeutics will post $-0.94 EPS for the current fiscal year.
Celldex Therapeutics, Inc (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.